Pentoxyverine

Dry cough caused by upper respiratory tract infection and acute or chronic bronchitis is a common clinical respiratory system symptom. If it attacks frequently, it will seriously affect the quality of life of patients. Pentoxyverine is a commonly used antitussive drug to solve this kind of non-productive dry cough. As a non-addictive central antitussive, it can directly inhibit the cough center in the medulla oblongata, and has mild atropine-like effect and local anesthetic effect at the same time. It can relax bronchial smooth muscle and reduce airway resistance. Its antitussive intensity is about 1/3 of that of codeine, with no addiction and tolerance. It is suitable for patients with non-productive dry cough of all ages, especially for the symptomatic treatment of paroxysmal dry cough caused by common cold and bronchitis.

At present, the market size of domestic pentoxyverine preparations is stable at around 300 million yuan, with an annual growth rate maintained at 2%-3%. It belongs to a mature general drug category with clinical rigid demand. The competitive landscape is dominated by generic drugs, with more than 20 domestic enterprises holding production approvals for preparations. This variety has been included in the National Essential Drug List and the Class A Medical Insurance List, with stable demand in the primary market. The domestic production capacity of the API supply side is sufficient, the overall market competition is sufficient, and the price fluctuation range is small.

The original research enterprise of pentoxyverine is Novartis, and the original trade name is Toclase. The core compound patent has expired worldwide in the 1970s. At present, the mainstream dosage forms include 25mg tablets, 15ml:150mg syrup, etc. The original research-related dosage forms have been included in the FDA Reference Listed Drug Catalog. No original research preparations have been imported into China, and most domestic reference preparations use marketed domestic generic drugs. As of now, the CDE API registration platform shows that 12 domestic enterprises have completed the A-status registration of pentoxyverine API, which can be legally supplied to preparation manufacturers. The domestically approved preparation varieties cover multiple dosage forms such as tablets, dripping pills and syrups. (Data as of July 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for pentoxyverine API. Most products are in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. They fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the use needs of enterprises in multiple scenarios such as quality research, registration and declaration, and daily inspection.